MRC Technology’s Centre for Therapeutics Discovery (CTD) is responsible for accessing early stage molecular targets emerging from academic research, for indications where there is a clear unmet need. It de-risks these targets by delivering potent and selective lead compounds or antibodies with demonstrable efficacy in a relevant disease model, ready for partnering with industry. Researchers can tell us about their novel targets through our Call for Targets.
CTD is divided into three sections:
The Biology department supports projects where the aim is to generate a small molecule drug rather than a therapeutic antibody. They work closely with the Chemistry department, and are divided into two sections; Assay Development and Screening, and Compound Profiling and Cellular Pharmacology.
The Chemistry department is responsible for the synthesis and delivery of novel chemical substances that are stepping stones on the path to developing new drugs.
The BioTherapeutics team uses patented techniques to generate therapeutic antibodies, and carry out affinity maturation and biophysical characterisation. They also offer a commercial antibody humanisation service, you can find more information about the service here.
Justin Bryans is our Director of Drug Discovery, and he is supported by Katy Kettleborough (Associate Director, Biology), Andy Merritt (Associate Director, Chemistry) and David Matthews (Associate Director, BioTherapeutics). To contact them, please visit the Our People page.
You can find out about any recent publications or posters that we have presented on the News page.